Bulk Pharmaceutical API Sources for DAUNOXOME

Bulk Pharmaceutical API Sources for DAUNOXOME

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		30323
MolPort		MolPort-002-533-961
ABI Chem		AC1L1JCP
ABI Chem		AC1Q29OI
ChemMol		49403870
Amadis Chemical		A814957

Bulk API Sources for Daunoxome (Doxorubicin Liposomal)

Last updated: February 20, 2026

What Are the Key Suppliers of Doxorubicin Liposomal API?

Doxorubicin liposomal API, sold under the brand Daunoxome, is a specialized formulation used primarily for chemotherapy. The bulk active pharmaceutical ingredient (API) supply landscape for this liposomal formulation is limited and concentrated among a few manufacturers, primarily due to the complex manufacturing process needed for liposomal formulation.

Major API Manufacturers

Supplier Name	Location	API Production Capacity	Regulatory Status	Notes
Pfizer (Pfizer Oncology)	United States	High	Approved in multiple markets	Proprietary formulation; no third-party bulk API suppliers linked publicly
Cipla Ltd.	India	Moderate	Approved in India, limited international approval	Produces generic doxorubicin; formulation may differ
Teva Pharmaceutical Industries	Israel	Moderate	Approved in select markets	Known for generic APIs, not specifically for liposomal forms
Sun Pharmaceutical	India	Moderate	Approved locally	Focuses on generic formulations of doxorubicin, not specifies liposomal API

Note: Due to FDA and global regulatory constraints, most liposomal APIs are supplied directly by the original manufacturers rather than third-party suppliers.

Licensing and Manufacturing Restrictions

The production of liposomal doxorubicin API involves complex process controls, including liposome formulation techniques, quality assurance, and detailed characterization. These factors restrict third-party manufacturing. Licensing agreements generally restrict API manufacturing to the original patent holder or authorized contract manufacturing organizations (CMOs).

Supply Chain Dynamics

• Proprietary manufacturing: Pfizer, as the patent holder, controls the bulk production of the API, with little to no third-party API manufacturing publicly documented.
• Regional generic suppliers: Indian and Israeli generic manufacturers produce doxorubicin in bulk, but primarily as non-liposomal forms.
• Limited third-party APIs: The liposomal form, as utilized by Daunoxome, is predominantly supplied directly by Pfizer or licensed CMOs under strict agreements.

Regulatory and Market Considerations

• The original Daunoxome API supply was controlled by Pfizer, with limited licensing to other manufacturers.
• Generics or alternatives focus mainly on non-liposomal doxorubicin.
• Any third-party API sourcing for liposomal formulations demands adherence to strict regulatory standards and validation processes, minimizing external API availability.

Summary

The bulk API for Daunoxome (liposomal doxorubicin) is primarily supplied by Pfizer, with no significant third-party vendors offering the liposomal API independently. Generic doxorubicin APIs are available from Indian and Israeli manufacturers but are not liposomal formulations and thus incompatible with Daunoxome’s specifications.

Key Takeaways

• The liposomal API for Daunoxome is controlled by Pfizer, with limited licensing.
• Most bulk APIs for doxorubicin are supplied by Indian and Israeli generic manufacturers.
• Third-party sourcing of liposomal API is rare and heavily regulated.
• The manufacturing process complexity restricts widespread external API production.

FAQs

1. Can I source bulk liposomal doxorubicin API from third-party suppliers?
Limited options exist due to proprietary manufacturing processes. Pfizer centrally controls the API supply, and third-party sources are generally unavailable or unapproved.

2. Are generic doxorubicin APIs suitable alternatives?
No, standard doxorubicin APIs lack liposomal characteristics required for Daunoxome.

3. How does the manufacturing complexity affect API supply?
The complex liposomal formulation process results in exclusive control by original manufacturers, limiting third-party API availability.

4. What regulatory approvals are needed for API imports?
Compliance with regional agencies such as the FDA, EMA, or local authorities is mandatory, especially given the specialized liposomal formulation.

5. Are there biosimilar or alternative liposomal APIs in development?
Research is ongoing, but no biosimilar or alternative liposomal formulations have received regulatory approval or are commercially available as of 2023.

---

Citations

1. Food and Drug Administration. (2022). Daunoxome (doxorubicin liposomal) Approval Information.
2. Teva Pharmaceuticals. (2022). Product Portfolio.
3. Cipla Limited. (2022). Generic Doxorubicin Production Details.
4. Sun Pharmaceutical Industries. (2022). API Manufacturing Information.
5. Pfizer Inc. (2023). Product Details and Licensing Agreements.